Es kann sich nur noch um Jahre handeln - 500 Beiträge pro Seite

[Profilos]

Hallo Leute

hat jemand irgendeine Ahnung wann man Phase III bei Heparin und
Insulin verläßt.
Die Ärztezunft ist ja ganz zuversichtlich.
Mal schauen was geht.
Weitere Info´s werden noch nachgereicht.

[Profilos]

07.08.2007 14:57
Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results

TARRYTOWN, N.Y., Aug. 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, (Nachrichten) Inc. today announced its financial results for the second quarter ended June 30, 2007.

"Emisphere's product pipeline is growing increasingly robust," said Michael V. Novinski, President/Chief Executive Officer of Emisphere Technologies, Inc. "In addition to the 10 products we have in various stages of clinical development, we have an additional 11 pre-clinical projects in our pipeline, six with partners and five without established collaborations. We are seeking to move our patented technology into a broad array of disease states, including obesity, osteoporosis, infectious disease, diabetes, CNS, erectile dysfunction and fertility treatment, among others."

Emisphere Technologies, Inc. will host a conference call to discuss second quarter results at 10:00 AM EDT today. A live Webcast of the conference call can be accessed through the company's Web site at: http://www.emisphere.com/. The live conference call dial-in number is: 1-800-819-9193 (US and Canada) or 1- 913-981-4911 (International). In addition, an archive of the Webcast can be accessed through the same link; an audio replay of the call will be available following the conference call by calling 1-888-203-1112 (US and Canada) or 1- 719-457-0820 (International). The conference replay PIN is 9045496.

Second Quarter Financial Results -- Operating expenses for the second quarter of 2007 were $9.9 million compared to $8.6 million in the second quarter of 2006 * $1.3 million increase in operating expenses is primarily the result of non-cash charges related to share-based payments -- Other expense second quarter 2007 were $2.6 million, compared to $0.3 million in the second quarter of 2006 * $2.3 million increase in other expenses is primarily the result of non-cash charges related to the change in fair value of derivative instruments -- Second quarter 2007 revenues were $0.4 million, compared to the $5.2 million in the second quarter of 2006 -- Second quarter 2007 operating loss of $9.5 million, compared to an operating loss of $3.4 million for the first quarter of 2006 -- Second quarter 2007 net loss was $12.1 million, or $0.43 per basic and diluted share, compared to a net loss of $3.8 million, or $0.14 per basic and diluted share for the second quarter of 2006 -- As of June 30, 2007, Emisphere has $8.9 million in cash and investments. The Company is currently evaluating various financing options to address its future cash needs that will enable the Company to continue operations through the fourth quarter of 2007 and beyond. Corporate and Product Developments

Emisphere has two Phase III products based on the compound salmon calcitonin in partnership with Novartis Pharma AG and its development partner, Nordic Bioscience:


-- One product relates to the prevention of osteoporosis and the other product relates to the prevention of osteoarthritis -- Osteoarthritis product has the potential to be the first disease- modifying drug that halts progression of the illness rather than treating symptoms -- Both products use Emisphere's eligen(R) delivery technology to provide salmon calcitonin for the first time as a convenient oral medication Emisphere has three products in Phase II: -- Development of recombinant human growth hormone ("rhGH") in collaboration with Novartis Pharma AG -- Continuing the development of oral heparin; discussions with the US Food and Drug Administration (FDA) has established a pathway for registration to proceed into complete Phase III for the use of oral heparin in the prevention of deep-vein thrombosis following elective total hip replacement. Emisphere is in current discussions with potential partners to complete the development of oral heparin in a collaborative arrangement. -- Continuing clinical development of oral insulin; an insulin/glucose clamp study with a new formulation is being planned over a three-month period starting early in the first quarter, which will provide further data and information on the dosage. Collaborative partnerships will then be investigated Emisphere has five products in Phase I: -- An Investigational New Drug application (IND) was filed by Genta Incorporated on gallium nitrate on July 31, 2007 -- A program continues on an improved oral formulation of the antiviral compound acyclovir with a pharmaceutical company outside of the United States -- A food-intake study for both GLP-1 and PYY will be undertaken later this year at University Hospital, Switzerland -- Parathyroid hormone continues on a progressive clinical development path in collaboration with Novaris Pharma AG Emisphere has 11 products in preclinical development: -- Six projects with partners in obesity, osteoporosis, infectious disease, diabetes, and CNS -- Five projects without established collaborations for the therapies of CNS, erectile dysfunction, cardiovascular disease, inflammation and pain, and fertility treatment -- Following completion of these pre-clinical projects, decisions would then be taken to possibly proceed into future collaborations with each of the partners for further pre-clinical or clinical development; projects without established collaborations will be assessed for continued development to the next step with or without a partner About Emisphere Technologies, Inc.

Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) technology. These molecules and compounds could be currently available or are in pre-clinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The Web site is: http://www.emisphere.com/.

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758).


EMISPHERE TECHNOLOGIES, INC. Condensed Statements of Operations (Unaudited) For the three and six months ended June 30, 2007 and 2006 (in thousands, except share and per share data) For the three months For the six months ended ended June 30, June 30, 2007 2006 2007 2006 Revenue $398 $5,220 $3,207 $6,916 Costs and expenses: Research and development 6,032 4,858 11,484 9,375 General and administrative expenses 3,638 2,812 7,784 5,614 Depreciation and amortization 270 972 583 1,962 Total costs and expenses 9,940 8,642 19,851 16,951 Operating loss (9,542) (3,422) (16,644) (10,035) Other (expense) and income: Beneficial conversion of convertible security - - - (12,215) Investment and other income 482 294 797 417 Change in fair value of derivative instruments (2,401) (56) 1,123 (7,620) Interest expense (643) (573) (1,267) (1,140) Total other (expense) and income (2,562) (335) 653 (20,558) Net (loss) income $(12,104) $(3,757) $(15,991) $(30,593) Net (loss) income per share, basic $(0.43) $(0.14) $(0.57) $(1.23) Net (loss) income per share, diluted $(0.43) $(0.14) $(0.60) $(1.23) Weighted average shares outstanding, basic 28,313,056 25,952,342 28,305,810 24,815,680 Weighted average shares outstanding, diluted 28,313,056 25,952,342 28,403,507 24,815,680 EMISPHERE TECHNOLOGIES, INC. Condensed Balance Sheets (Unaudited) As of June 30, 2007 and December 31, 2006 (in thousands) June 30, December 31, 2007 2006 Assets: Cash, cash equivalents, restricted cash and investments $8,939 $21,533 Accounts receivable 487 216 Prepaid expenses and other current assets 893 1,082 Total current assets 10,319 22,831 Equipment and leasehold improvements, net 2,247 2,652 Purchased technology, net 1,675 1,794 Other assets 798 815 Total Assets $15,039 $28,092 Liabilities and stockholders' deficit: Current liabilities $9,016 $9,454 Notes payable 25,994 24,744 Other long-term liabilities 172 - Stockholders' deficit (20,143) (6,106) Total liabilities and stockholders' deficit $15,039 $28,092





Klicken Sie hier, um weitere aktuelle Nachrichten zum Unternehmen zu finden:

EMISPHERE TECHNOLOGIES



11:19: Nemetschek AG
09:37: United Labels AG
09:31: Catalis N.V.
08:55: phion AG
08:55: HTI - High Tech Indust
08:49: SW Umwelttechnik Stois
08:31: Electronics Line 3000
08:13: freenet AG
08:13: CENIT AG Systemhaus
08:13: Christ Water Technolog
08:07: Sparkassen Immobilien
08:07: Palfinger AG
07:55: Travel24.com AG
07:49: Basler AG
07:37: voestalpine AG
07:37: Techem AG
07:31: Vizrt
06:55: cash.life AG
07.08. IKB Deutsche Industrie
07.08. GESCO AG
07.08. Süss MicroTec AG
07.08. PRO DV Software AG
07.08. Bien-Zenker AG
07.08. Alexanderwerk AG
07.08. NORDWEST Handel AG
07.08. 3U TELECOM AG
07.08. Air Berlin PLC
07.08. ALNO AG

In der vergangenen Woche gaben die Börsen Aktienmärkten weltweit deutlich nach. Wie beurteilen Sie derzeit die Aussichten?
Das Schlimmste ist überstanden. Der langfristige Aufwärtstrend bleibt bestehen, bald gibt es neue Hochs.
Es wird zunächst wieder aufwärts gehen, richtig krachen wird es dann erst im September/Oktober.
Die Märkte drehen in eine volatile Seitwärtsbewegung ein. Kein Grund zur Sorge, aber Stockpicking ist angesagt.
Die Kurse werden kurzfristig noch weiter fallen, aber sich dann wieder freundlich entwickeln.
Die Kursrückgänge von vergangener Woche sind erst der Anfang: Wir befinden uns nach 4 Jahren Hausse nun am Beginn einer Baisse.

Ergebnis/Archiv

[Profilos]

Mit Heparin u. Insulin meinte ich natürlich die Orale Version.
Sorry

[Profilos]

Emisphere Technologies Inc On this page: Select Article Hoover's Profile Stock Quote Stock Chart Company News --------------- Or search: - The Web - Images - News - Blogs - Shopping
Emisphere Technologies Inc
Hoover's Profile
Batch Made Easy
Put DeltaV Batch at your fingertips for results - easy.
www.EasyDeltaV.com/Batch




Home > Library > Business > Hoover's Profiles Emisphere Technologies, Inc. (NASDAQ (GM):EMIS) Company Financials
Income Statement
Balance Sheet
Cash Flow Statement


Contact Information
Emisphere Technologies, Inc.
765 Old Saw Mill River Rd.
Tarrytown, NY 10591
NY Tel. [phone]
Fax [phone]
Type: Public
On the web: http://www.emisphere.com
Employees: 118
Employee growth: 2.6%
Development-stage Emisphere Technologies is creating drug-delivery systems for people who literally can't stomach the treatments they need. The company's drug delivery system is intended to allow the oral delivery of medicines that, for a variety of reasons, cannot currently be offered to patients in an oral form, including drugs for osteoporosis, diabetes, growth disorders, cardiovascular disease, and other health problems. Emisphere is developing a solid oral dose of heparin, insulin, and allergy treatment cromolyn sodium. The company has collaborative partnerships with Novartis and Roche. Emisphere was formed in 1986.

Key numbers for fiscal year ending December, 2006:
Sale: $7.3M
One year growth: 105.1%
Net income: ($41.8)M


Officers:
SVP, Business Development: Lewis H. Bender
President and CEO: Michael V. Novinski


Competitors:
Bristol-Myers Squibb
GlaxoSmithKline
Sanofi-Aventis

[Profilos]

ganz interresante Zusammensetzung:

WICHTIGSTE INSTITUTIONELLE EIGENTÜMER

Eigentümer Aktien % Out Wert* Gemeldet
ATTICUS CAPITAL LP 2303800 8.13 $11150392 30-Jun-07
DEUTSCHE BANK AKTIENGESELLSCHAFT 1524974 5.38 $7380874 30-Jun-07
DIMENSIONAL FUND ADVISORS INC 655753 2.31 $3173844 30-Jun-07
Barclays Global Investors UK Holdings Ltd 636070 2.25 $3078578 30-Jun-07 MHR Fund Management, LLC 4210000 14.86 $20376400 30-Jun-07
VANGUARD GROUP, INC. (THE) 260771 .92 $1262131 30-Jun-07
ROYCE & ASSOCIATES, INC. 163200 .58 $789888 30-Jun-07
CALPERS (CALIFORNIA-PUBLIC EMPLOYEES RETIREMENT SYSTEM) 116400 .41 $563376 30-Jun-07
CITIGROUP INC. 114760 .41 $555438 30-Jun-07
SHAW D.E. & CO., INC. 73624 .26 $235596 31-Mar-07


WICHTIGSTE INVESTMENTFONDS EIGENTÜMER

Eigentümer Aktien % Out Wert* Gemeldet
DFA U.S. MICRO CAP PORTFOLIO 254928 .90 $1279738 28-Feb-07
ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND 208517 .74 $667254 31-Mar-07
ROYCE MICRO CAP TRUST 163200 .58 $522240 31-Mar-07
ISHARES RUSSELL 2000 INDEX FD 142721 .50 $456707 31-Mar-07
VANGUARD EXTENDED MARKET INDEX FUND 139970 .49 $447904 31-Mar-07
COLLEGE RETIREMENT EQUITIES FUND-STOCK ACCOUNT 136515 .48 $436848 31-Mar-07
ISHARES RUSSELL 2000 GROWTH INDEX FD 94423 .33 $302153 31-Mar-07
DFA U.S. SMALL CAP SERIES 86842 .31 $435946 28-Feb-07
VANGUARD TOTAL STOCK MARKET INDEX FUND 84641 .30 $270851 31-Mar-07
DFA U.S. SMALL CAP VALUE SERIES 74132 .26 $372142 28-Feb-07


Transaktionen von Insidern